123 AZACITIDINE (AZA) COMBINED WITH IDARUBICIN (IDA) IN HIGHER RISK MDS (HRMDS) – RESULTS OF A PHASE I/II STUDY BY THE GFM von Sebert, M, Ades, L, Stamatoullas, A, Braun, T, Delaunay, J, de Renzis, B, Jeddi, R, Meddeb, B, Berger, M. Hunault, Samey, B, Chermat, F, Chaffaut, C, Chevert, S, Fenaux, P

Volltext

O-011 Azacitidine (AZA) + idarubicin (IDA) in untreated high-risk MDS – A GFM phase I/II study von Ades, L, De Renzis, B, Jeddi, R, Delaunay, J, Braun, T, Hunault-Berger, M, Stamatoullas, A, Sanhes, L, Samey, B, Chermat, F, Meddeb, B, Fenaux, P

Volltext

P-281 Escalating doses of clofarabine (CLO) for high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia post-MDS (sAML) failing azacitidine (AZA) von Braun, T, Raffoux, E, Prebet, T, Stamatoullas, A, Bréchignac, S, Dreyfus, F, Samey, B, Adès, L, Vey, N, Dombret, H, Fenaux, P, Gardin, C

Volltext

Allogeneic stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in recent years: a retrospective EBMT analysis of patients transplanted in first remiss... von Ottmann, O.G, Labopin, M, Ruutu, T, Socie, G, Bekassy, A, Rambaldi, A, Samey, B, Esteve, J, Rocha, V

Volltext